New drug shows promise in preventing transplant complication
NCT ID NCT02867384
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether the drug obinutuzumab can prevent chronic graft-versus-host disease (cGVHD), a common and serious complication after a stem cell transplant. 181 people who had a stem cell transplant took part. The goal was to see if obinutuzumab could reduce the need for steroids to treat cGVHD in the first year after transplant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT VS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
-
Masonic Cancer Center
Minneapolis, Minnesota, 55455, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Stanford University
Palo Alto, California, 94305, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a safer dose of an old drug shield vulnerable children from deadly fungal infections?
- Gene analysis may unlock secrets of bone marrow transplant complication
- Aggressive chemo plus stem cell transplant tested for breast cancer
- Herbal extract shows promise for stiff skin and joints in transplant survivors
- Immune-Guided drug timing could cut CMV prevention after transplant
- New drug shows promise in preventing Graft-Versus-Host disease